Tag:

Daiichi Sankyo

Latest Headlines

Latest Headlines

After 4-year Benicar review, FDA slaps aside heart-risk worries

After four years of sifting data, the FDA says it found "no clear evidence" that Daiichi Sankyo's blockbuster blood pressure drug increased the risk of heart attack. But the agency will require new safety-related data on Benicar's official label.

The man behind Daiichi Sankyo buyout of Ranbaxy gives up chairman's role

One of the execs who masterminded Daiichi Sankyo's acquisition of Ranbaxy Laboratories--and then lived with it as the generic drugmaker drew the Japanese company into a whirlwind of regulatory issues--is stepping down as chairman.

Daiichi Sankyo turns over domestic logistics to Yasuda Warehouse

In an effort to control costs, Japan's Daiichi Sankyo is reworking its manufacturing network and says that in Japan, it has even turned over some of its warehousing and logistics to another company.

Costs from FDA actions undermine Ranbaxy's earnings

Ranbaxy Laboratories continues to spend big as it tries to deal with regulatory issues at plants banned by the FDA, issues that pushed it into the arms of competitor Sun Pharmaceutical. The more than $20 million in write-downs on inventory and goodwill it had to take in the last quarter led to a loss, even as sales improved slightly.

10 big brands keep pumping out big bucks, with a little help from price hikes

Thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage. We thought we'd look into the products whose prices have increased the most since 2007, to see how and why their prices are leaping.

Daiichi Sankyo lays out road map for Ranbaxy deal with Sun

Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its revamp by Sun might put them in peril.

Sources: Sun to phase out Ranbaxy brand in U.S.

Mention Ranbaxy drugs to some wholesalers and U.S. doctors these days, and they will respond negatively. And so the Ranbaxy brand looks to be on its way out when Sun Pharmaceutical completes its $3.2 billion acquisition of Ranbaxy Laboratories later this year.

Daiichi Sankyo sells off Ranbaxy's problems to Sun Pharma

Daiichi Sankyo has found one way to deal with Ranbaxy Laboratories' persistent quality problems: Hand them off to somebody else to fix. That is what the Japanese drugmaker will do with an agreement to sell Ranbaxy to Sun Pharmaceutical in an all stock deal that will give Daiichi Sankyo a 9% stake in Sun.

Sun Pharma hopes to turn fortunes of Ranbaxy around with $3.2B buyout

Sun Pharmaceutical has been shopping for deals that would give it more exposure to the U.S. market, and now it has pulled off a stunner. The Indian drugmaker will pay $3.2 million to buy competitor Ranbaxy Laboratories, a company with serious issues but one with big potential in the world's largest market.

Daiichi misses H5N1 vaccine production goal after low yields slash output

The seed strain is often to blame for low yields of vaccines to protect against pandemic flu strains H1N1 and H5N1, but Daiichi Sankyo has now encountered difficulties when processing the vaccine, leaving the drugmaker unable to hit the H5N1 vaccine production target it agreed upon with the Japanese government.